Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.88 |
| ▸ | PIK3R2 | O00459 | 12/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813059 | 0.94 | PIK3CD (1.00) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| Trifluoroacetic Acid SCHEMBL15487455 | 0.93 | PIK3CD (0.75) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL12813130 | 0.87 | PIK3CD (0.84) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL12812992 | 0.87 | PIK3CD (0.87) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL12965157 | 0.84 | PIK3CD (0.82) | PIK3CDPIK3R2PIK3CG | |
| Trifluoroacetic Acid SCHEMBL12812980 | 0.84 | PIK3CD (0.62) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL12813132 | 0.84 | PIK3CD (0.81) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL12813005 | 0.82 | PIK3CD (0.78) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL12813127 | 0.79 | PIK3CD (0.72) | PIK3CDPIK3R2PIK3CGPIK3CBPIK3R1 | |
| SCHEMBL9929092 | 0.78 | PIK3CD (0.79) | PIK3CDPIK3R2PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126948-B2 | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012135009-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057912-A1 | PYRIMIDINE-4,6-DIAMINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3R2 35/4885PIK3CG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.